Michael Beck

18.9k total citations · 1 hit paper
213 papers, 12.2k citations indexed

About

Michael Beck is a scholar working on Physiology, Epidemiology and Rheumatology. According to data from OpenAlex, Michael Beck has authored 213 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 204 papers in Physiology, 92 papers in Epidemiology and 66 papers in Rheumatology. Recurrent topics in Michael Beck's work include Lysosomal Storage Disorders Research (202 papers), Trypanosoma species research and implications (89 papers) and Glycogen Storage Diseases and Myoclonus (64 papers). Michael Beck is often cited by papers focused on Lysosomal Storage Disorders Research (202 papers), Trypanosoma species research and implications (89 papers) and Glycogen Storage Diseases and Myoclonus (64 papers). Michael Beck collaborates with scholars based in Germany, United Kingdom and United States. Michael Beck's co-authors include Atul Mehta, Gere Sunder‐Plassmann, Christoph Kampmann, Catharina Whybra, Roberto Giugliani, Joseph Muenzer, Markus Ries, J. E. Wraith, Andreas Gal and Uma Ramaswami and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Michael Beck

207 papers receiving 11.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

2004 601 citations Atul Mehta, Urs Widmer et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Michael Beck	10.9k	5.2k	3.7k	2.4k	2.3k	213	12.2k
Gregory M. Pastores	7.5k 0.7×	3.1k 0.6×	1.4k 0.4×	2.3k 1.0×	2.8k 1.2×	204	8.8k
Priya S. Kishnani	7.6k 0.7×	2.2k 0.4×	6.4k 1.7×	2.4k 1.0×	770 0.3×	456	12.8k
Nathalie Guffon	5.2k 0.5×	2.4k 0.4×	1.7k 0.5×	1.1k 0.4×	914 0.4×	138	6.5k
Joseph Muenzer	5.2k 0.5×	2.3k 0.4×	1.8k 0.5×	805 0.3×	843 0.4×	128	6.9k
Ans T. van der Ploeg	6.5k 0.6×	1.5k 0.3×	4.3k 1.2×	1.6k 0.7×	619 0.3×	228	8.2k
Joel Charrow	4.1k 0.4×	2.8k 0.5×	1.2k 0.3×	1.3k 0.6×	1.4k 0.6×	143	7.1k
Anna Tylki‐Szymańska	4.1k 0.4×	1.8k 0.4×	987 0.3×	1.2k 0.5×	1.4k 0.6×	263	5.4k
Ashok Vellodi	3.9k 0.4×	1.7k 0.3×	931 0.3×	901 0.4×	1.2k 0.5×	105	4.9k
Eugen Mengel	4.0k 0.4×	1.3k 0.2×	1.1k 0.3×	1.1k 0.4×	802 0.3×	137	4.7k
Robert J. Hopkin	2.8k 0.3×	1.5k 0.3×	1.2k 0.3×	710 0.3×	716 0.3×	189	5.8k

Countries citing papers authored by Michael Beck

Since Specialization

Citations

This map shows the geographic impact of Michael Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Beck more than expected).

Fields of papers citing papers by Michael Beck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Beck. The network helps show where Michael Beck may publish in the future.

Co-authorship network of co-authors of Michael Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Beck. A scholar is included among the top collaborators of Michael Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Beck. Michael Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borgwardt, Line, Nathalie Guffon, Yasmina Amraoui, et al.. (2018). Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double‐blind, randomised, placebo‐controlled trial. Journal of Inherited Metabolic Disease. 41(6). 1215–1223. 38 indexed citations

Müller‐Forell, Wibke, Maurizio Scarpa, Paul Harmatz, et al.. (2013). Development of a Scoring System to Evaluate the Severity of Craniocervical Spinal Cord Compression in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome). JIMD Reports. 11. 65–72. 24 indexed citations

Muenzer, Joseph, Michael Beck, Roberto Giugliani, et al.. (2011). Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey. Genetics in Medicine. 13(2). 102–109. 77 indexed citations

Clarke, Joe T.R., Roberto Giugliani, Gere Sunder‐Plassmann, et al.. (2011). Impact of Measures to Enhance the Value of Observational Surveys in Rare Diseases: The Fabry Outcome Survey (FOS). Value in Health. 14(6). 862–866. 9 indexed citations

Beck, Michael. (2011). Lysosomale Speicherkrankheiten. Monatsschrift Kinderheilkunde. 159(9). 821–826. 1 indexed citations

Decker, Celeste, Zi‐Fan Yu, Roberto Giugliani, et al.. (2010). Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine. 3(2). 89–100. 52 indexed citations

Schermuly, Ingrid, Matthias J. Müller, Isabel Keller, et al.. (2010). Neuropsychiatric symptoms and brain structural alterations in Fabry disease. European Journal of Neurology. 18(2). 347–353. 43 indexed citations

Beck, Michael, Joseph Muenzer, & Maurizio Scarpa. (2010). Evaluation of disease severity in mucopolysaccharidoses. Journal of Pediatric Rehabilitation Medicine. 3(1). 39–46. 20 indexed citations

Muenzer, Joseph, Michael Beck, Christine M. Eng, et al.. (2010). Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genetics in Medicine. 13(2). 95–101. 173 indexed citations

10.

Beck, Michael. (2009). Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease. SHILAP Revista de lepidopterología. 1 indexed citations

11.

Giannini, Edward H., Atul Mehta, Max J. Hilz, et al.. (2009). A validated disease severity scoring system for Fabry disease. Molecular Genetics and Metabolism. 99(3). 283–290. 48 indexed citations

12.

Thomaidis, Thomas, Manfred Relle, Christoph Brochhausen, et al.. (2008). Downregulation of α-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney International. 75(4). 399–407. 21 indexed citations

13.

Wraith, J. E., Michael Beck, Roberto Giugliani, et al.. (2008). Initial report from the Hunter Outcome Survey. Genetics in Medicine. 10(7). 508–516. 139 indexed citations

14.

Wraith, J. E., Maurizio Scarpa, Michael Beck, et al.. (2007). Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics. 167(3). 267–277. 365 indexed citations

15.

Beck, Michael, et al.. (2007). Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey. Clinical Journal of Pain. 23(6). 535–542. 100 indexed citations

16.

Mehta, Atul C., Michael Beck, Aleš Linhart, Gere Sunder‐Plassmann, & Urs Widmer. (2006). History of lysosomal storage diseases: an overview. 28(1). 95–95. 11 indexed citations

17.

Mehta, A, Michael Beck, & Gere Sunder‐Plassmann. (2006). Biomarkers in lysosomal storage diseases -- Fabry Disease: Perspectives from 5 Years of FOS. Addictive Behaviors. 137. 107536–107536. 3 indexed citations

18.

Muenzer, Joseph, J. E. Wraith, Michael Beck, et al.. (2006). A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genetics in Medicine. 8(8). 465–473. 457 indexed citations

19.

Dehout, F., Andreas Schwarting, A. García de Lorenzo, et al.. (2005). Anemia is a new complication in Fabry disease: Data from the Fabry Outcome Survey. Kidney International. 67(5). 1955–1960. 25 indexed citations

20.

Kampmann, Christoph, Frank Baehner, Catharina Whybra, et al.. (2002). Cardiac manifestations of Anderson–Fabry disease in heterozygous females. Journal of the American College of Cardiology. 40(9). 1668–1674. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact